Danny Levin is President and R&D Director at Norac Pharma. He manages all aspects of the business but maintains particular interest in leading process research and development, concluding with new product manufacturing, for our contract pharma projects. Danny has accumulated around 28 years of industrial process R&D and manufacturing experience in Europe, Canada, USA and India, working with ICI, Zeneca, AstraZeneca, Avecia, Torcan and Piramal Healthcare, before moving to Norac Pharma in 2007.
Danny's academic qualifications comprise 1st class honors Bachelors, Masters and PhD degrees from Cambridge University in the UK. He is widely published in both chemistry literature and patent applications, with over 100 citations to his work and has been recognized with Fellowship of the UK Royal Society of Chemistry. He has also taught synthetic chemistry as Adjunct Professor at Toronto's York University.
Danny brings to Norac Pharma a breadth of experience in complex pharmaceutical chemistry process R&D based on sound mechanistic and kinetic understanding. He has demonstrated manufacturing achievements across a wide range of synthetic targets and scales of manufacture. Danny has been responsible for defining process chemistry and supplying API across all phases of pharma development, from discovery through preclinical, clinical trials, process validation, commercial optimization and life cycle extension. This has been done with strong attention to regulatory implications (including successful defense to FDA Advisory Committee). Danny's wide range of experience allows him to tailor Norac Pharma process R&D offering to suit client needs, well matched to drug development phase.
Please don’t hesitate to contact us to discuss your drug development needs in strictest confidence and without obligation.